Companies › Sinocelltech
10 active drug programs in 16 registered trials: 7 Phase 3, 6 Phase 1, 2 Phase 2, 1 Phase 4; Oncology, Infectious disease, Immunology, Hematology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SCTC21C anti-CD38 monoclonal antibody | CD38 | Phase 3 | Multiple Myeloma (MM); Amyloidosis; Relapsed or Refractory Hematologic Malignancies | Feb 2027 |
| SCTB35 Unclear - investigational compound | – | Phase 3 | DLBCL - Diffuse Large B Cell Lymphoma; Follicular Lymphoma (FL); System Lupus Erythematosus | May 2027 |
| SCTB14 | – | Phase 3 | Non-Small Cell Lung Carcinoma (NSCLC) | Jul 2027 |
| Recombinant 14-Valent Human Papillomavirus Vaccine (Insect Cell) 14-valent HPV vaccine | – | Phase 3 | HPV InfectioN | Aug 2028 |
| Omfiloctocog Alfa (SCT800) Coagulation factor VIII exogenous protein | F8 | Phase 3 | Haemophilia A; Hemophilia A With Inhibitor | Dec 2028 |
| SCT650C Anti-IL-17A antibody | IL17A | Phase 2 | Hidradenitis Suppurativa (HS) | Mar 2027 |
| SCTB41 | – | Phase 2 | Double Blind; Advanced Malignant Solid Tumours | Apr 2027 |
| SCT520FF | – | Phase 1 | nAMD | Jan 2027 |
| SCTV02 Recombinant respiratory syncytial virus (RSV) vaccine | – | Phase 1 | Respiratory Syncytial Virus | Jul 2027 |
| SCTB39-1 | – | Phase 1 | Advanced Malignant Solid Tumor | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05888870 | Omfiloctocog Alfa (SCT800) | Phase 4 | Hemophilia A With Inhibitor | Hematology | Dec 2026 |
| NCT06672536 | SCT520FF | Phase 1 | nAMD | Ophthalmology | Jan 2027 |
| NCT06252298 | SCTC21C | Phase 1 | Relapsed or Refractory Hematologic Malignancies | Oncology | Feb 2027 |
| NCT07244510 | SCT650C | Phase 2 | Hidradenitis Suppurativa (HS) | Immunology | Mar 2027 |
| NCT06600022 | SCTB41 | Phase 1 | Advanced Malignant Solid Tumours | Oncology | Apr 2027 |
| NCT06841042 | SCTB35 | Phase 1 | System Lupus Erythematosus | Immunology | May 2027 |
| NCT07362459 | SCTB14 | Phase 3 | Non-Small Cell Lung Carcinoma (NSCLC) | Oncology | Jul 2027 |
| NCT06754605 | SCTV02 | Phase 1 | Respiratory Syncytial Virus | Infectious disease | Jul 2027 |
| NCT07570823 | SCTB35 | Phase 3 | DLBCL - Diffuse Large B Cell Lymphoma | Oncology | Nov 2027 |
| NCT07297329 | SCTC21C | Phase 3 | Multiple Myeloma (MM) | Oncology | Dec 2027 |
| NCT07388602 | SCTC21C | Phase 3 | Amyloidosis | Metabolic and endocrine | Dec 2027 |
| NCT07562022 | SCTB35 | Phase 3 | Follicular Lymphoma (FL) | Oncology | May 2028 |
| NCT07050641 | SCTB39-1 | Phase 1 | Advanced Malignant Solid Tumor | Oncology | Jun 2028 |
| NCT06041061 | Recombinant 14-Valent Human Papillomavirus Vaccine (Insect Cell) | Phase 3 | HPV InfectioN | Infectious disease | Aug 2028 |
| NCT07437404 | Omfiloctocog Alfa (SCT800) | Phase 3 | Haemophilia A | Hematology | Dec 2028 |
| NCT07662395 | SCTB41 | Phase 2 | Double Blind | Oncology | Jan 2030 |
Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Innovent Biopharmaceutical Technology (Hangzhou) Chipscreen Biosciences Telix Pharmaceuticals (Innovations)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.